Filter

Refine by collections

Refine by date

—
  • Print
  • Save

Search Results

You are looking at 1 - 10 of 401 items for :

  • "replacement" x
Clear All
Guido Zavatta Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy

Search for other papers by Guido Zavatta in
Google Scholar
PubMed Close
and
Bart L Clarke Mayo Clinic, Rochester, Minnesota, USA

Search for other papers by Bart L Clarke in
Google Scholar
PubMed Close

replacement therapy. Since then a growing body of clinical studies has been published describing the long-term effects of recombinant human parathyroid hormone rhPTH(1–84), other forms of parathyroid hormone-based therapies, and PTH receptor 1 (PTHR1) agonist

Article Type:
Review Article
DOI:
https://doi.org/10.1530/EC-20-0366
Volume/Issue:
Volume 9: Issue 10
Open access
Angelica Sharma Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK

Search for other papers by Angelica Sharma in
Google Scholar
PubMed Close
,
Katharine Lazarus Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK

Search for other papers by Katharine Lazarus in
Google Scholar
PubMed Close
,
Deborah Papadopoulou Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK

Search for other papers by Deborah Papadopoulou in
Google Scholar
PubMed Close
,
Hemanth Prabhudev Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK

Search for other papers by Hemanth Prabhudev in
Google Scholar
PubMed Close
,
Tricia Tan Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK
Department of Clinical Biochemistry, North West London Pathology, London, UK

Search for other papers by Tricia Tan in
Google Scholar
PubMed Close
,
Karim Meeran Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK

Search for other papers by Karim Meeran in
Google Scholar
PubMed Close
, and
Sirazum Choudhury Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK
Department of Clinical Biochemistry, North West London Pathology, London, UK

Search for other papers by Sirazum Choudhury in
Google Scholar
PubMed Close

mortality ( 2 ). Replacement with glucocorticoid therapy is the mainstay of treatment, with an objective to mimic the circadian cortisol profile ( 3 ). Current guidelines recommend the use of hydrocortisone in divided doses or low-dose (3–5 mg

Article Type:
Research Article
Collections:
Adrenal
DOI:
https://doi.org/10.1530/EC-23-0097
Volume/Issue:
Volume 12: Issue 8
Open access
Johan Verhelst Department of Endocrinology, ZNA Middelheim Hospital, Antwerp, Belgium

Search for other papers by Johan Verhelst in
Google Scholar
PubMed Close
,
Anders F Mattsson Pfizer Endocrine Care, Pfizer Health AB, Sollentuna, Sweden

Search for other papers by Anders F Mattsson in
Google Scholar
PubMed Close
,
Cecilia Camacho-Hübner Pfizer Endocrine Care, Pfizer, Inc., New York, New York, USA

Search for other papers by Cecilia Camacho-Hübner in
Google Scholar
PubMed Close
,
Anton Luger Division of Endocrinology and Metabolism, Medical University and General Hospital, Vienna, Austria

Search for other papers by Anton Luger in
Google Scholar
PubMed Close
, and
Roger Abs Antwerp Centre for Endocrinology, Antwerp, Belgium

Search for other papers by Roger Abs in
Google Scholar
PubMed Close

particular relevance as an increased cardiovascular mortality has been found in patients with hypopituitarism receiving conventional hormonal replacement without GH ( 10 , 11 , 12 ). A recent KIMS study assessing GHD patients with MetS before GH replacement

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-18-0096
Volume/Issue:
Volume 7: Issue 5
Open access
Charlotte Höybye Department of Endocrinology, Department of Molecular Medicine and Surgery, Metabolism and Diabetology, Karolinska University Hospital, 171 76 Stockholm, Sweden
Department of Endocrinology, Department of Molecular Medicine and Surgery, Metabolism and Diabetology, Karolinska University Hospital, 171 76 Stockholm, Sweden

Search for other papers by Charlotte Höybye in
Google Scholar
PubMed Close
,
Erik Wahlström Department of Endocrinology, Department of Molecular Medicine and Surgery, Metabolism and Diabetology, Karolinska University Hospital, 171 76 Stockholm, Sweden

Search for other papers by Erik Wahlström in
Google Scholar
PubMed Close
,
Petra Tollet-Egnell Department of Endocrinology, Department of Molecular Medicine and Surgery, Metabolism and Diabetology, Karolinska University Hospital, 171 76 Stockholm, Sweden

Search for other papers by Petra Tollet-Egnell in
Google Scholar
PubMed Close
, and
Gunnar Norstedt Department of Endocrinology, Department of Molecular Medicine and Surgery, Metabolism and Diabetology, Karolinska University Hospital, 171 76 Stockholm, Sweden

Search for other papers by Gunnar Norstedt in
Google Scholar
PubMed Close

with healthy controls, and changes in metabolic profile during GH treatment and after discontinuation of GH replacement was observed. The aims of this study were to detect the levels of serum metabolome in GHD patients and healthy subjects and to find

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-14-0098
Volume/Issue:
Volume 3: Issue 4
Open access
David J F Smith Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK

Search for other papers by David J F Smith in
Google Scholar
PubMed Close
,
Hemanth Prabhudev Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK

Search for other papers by Hemanth Prabhudev in
Google Scholar
PubMed Close
,
Sirazum Choudhury Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK
Department of Clinical Biochemistry, Imperial College Healthcare NHS Trust, London, UK
Department of Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK

Search for other papers by Sirazum Choudhury in
Google Scholar
PubMed Close
, and
Karim Meeran Department of Endocrinology, Imperial College Healthcare NHS Trust, London, UK
Department of Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK

Search for other papers by Karim Meeran in
Google Scholar
PubMed Close

mineralocorticoid production in primary adrenal failure. The mainstay of treatment is glucocorticoid replacement, with either hydrocortisone or prednisolone ( 2 ). Both work by binding to the glucocorticoid receptor (GR) for which prednisolone has the greater

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-17-0257
Volume/Issue:
Volume 6: Issue 8
Open access
Charlotte Höybye Department of Endocrinology and Department of Molecular Medicine and Surgery, Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden

Search for other papers by Charlotte Höybye in
Google Scholar
PubMed Close
,
Beverly M K Biller Neuroendocrine Unit, Massachusetts General Hospital, Massachusetts General Hospital, Boston, Massachusetts, USA

Search for other papers by Beverly M K Biller in
Google Scholar
PubMed Close
,
Jean-Marc Ferran Qualiance ApS, Copenhagen, Denmark

Search for other papers by Jean-Marc Ferran in
Google Scholar
PubMed Close
,
Murray B Gordon Allegheny Neuroendocrinology Center, Division of Endocrinology, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA

Search for other papers by Murray B Gordon in
Google Scholar
PubMed Close
,
Nicky Kelepouris US Medical Affairs-Rare Endocrine Disorders, Novo Nordisk, Inc, Plainsboro, New Jersey, USA

Search for other papers by Nicky Kelepouris in
Google Scholar
PubMed Close
,
Navid Nedjatian Global Medical Affairs – Rare Endocrine Disorders, Novo Nordisk Health Care AG, Zurich, Switzerland

Search for other papers by Navid Nedjatian in
Google Scholar
PubMed Close
,
Anne H Olsen Epidemiology, Novo Nordisk A/S, Soborg, Denmark

Search for other papers by Anne H Olsen in
Google Scholar
PubMed Close
, and
Matthias M Weber Unit of Endocrinology, 1, Medical Department, University Hospital, Universitätsmedizin Mainz, der Johannes Gutenberg-Universität, Mainz, Germany

Search for other papers by Matthias M Weber in
Google Scholar
PubMed Close

quality of life, an adverse lipid profile and an increased risk for cardiovascular (CV)-associated disease, diabetes and metabolic syndrome vs healthy adults ( 4 , 5 , 6 , 7 ). The use of growth hormone (GH) replacement therapy in AGHD has been shown

Article Type:
Research Article
Collections:
Cardiovascular
DOI:
https://doi.org/10.1530/EC-22-0267
Volume/Issue:
Volume 12: Issue 1
Open access
M Ahmid Developmental Endocrinology Research Group, Royal Hospital for Children, School of Medicine, University of Glasgow, Glasgow, UK

Search for other papers by M Ahmid in
Google Scholar
PubMed Close
,
C G Perry Department of Endocrinology, Queen Elizabeth University Hospitals, Glasgow, UK

Search for other papers by C G Perry in
Google Scholar
PubMed Close
,
S F Ahmed Developmental Endocrinology Research Group, Royal Hospital for Children, School of Medicine, University of Glasgow, Glasgow, UK

Search for other papers by S F Ahmed in
Google Scholar
PubMed Close
, and
M G Shaikh Developmental Endocrinology Research Group, Royal Hospital for Children, School of Medicine, University of Glasgow, Glasgow, UK

Search for other papers by M G Shaikh in
Google Scholar
PubMed Close

treatment during transition, especially with treatment costing up to £5000 per year in adulthood ( 7 ). The current guideline has approved continuation of GH replacement in those who were confirmed to have persistent GHD through the transition phase

Article Type:
Review Article
DOI:
https://doi.org/10.1530/EC-16-0024
Volume/Issue:
Volume 5: Issue 3
Open access
Guillem Cuatrecasas Endocrinology Department, Hospital Quiron-Teknon, CPEN S.L., Barcelona, Spain
Universitat Oberta Catalunya (UOC), Barcelona, Spain

Search for other papers by Guillem Cuatrecasas in
Google Scholar
PubMed Close
,
Hatice Kumru Institut Guttmann, Institut Universitari de Neurorehabilitació Adscrit a la UAB, Barcelona, Spain
Univ Autònoma de Barcelona, Cerdanyola del Vallès, Spain
Fundació Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol, Barcelona, Spain

Search for other papers by Hatice Kumru in
Google Scholar
PubMed Close
,
M Josep Coves Endocrinology Department, Hospital Quiron-Teknon, CPEN S.L., Barcelona, Spain

Search for other papers by M Josep Coves in
Google Scholar
PubMed Close
, and
Joan Vidal Institut Guttmann, Institut Universitari de Neurorehabilitació Adscrit a la UAB, Barcelona, Spain
Univ Autònoma de Barcelona, Cerdanyola del Vallès, Spain
Fundació Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol, Barcelona, Spain

Search for other papers by Joan Vidal in
Google Scholar
PubMed Close

signaling pathway) both in animals and humans, as seen in vitro ( 13 ). In order to assess (1) frequency of GHD in chronic SCI patients and (2) the efficacy and safety of GH replacement therapy in SCI patients with GH deficiency, we designed a

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-18-0296
Volume/Issue:
Volume 7: Issue 10
Open access
Mark R Postma Department of Endocrinology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Search for other papers by Mark R Postma in
Google Scholar
PubMed Close
,
Pia Burman Department of Endocrinology, Skane University Hospital Malmö, University of Lund, Lund, Sweden

Search for other papers by Pia Burman in
Google Scholar
PubMed Close
, and
André P van Beek Department of Endocrinology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Search for other papers by André P van Beek in
Google Scholar
PubMed Close

. It therefore usually occurs in the context of additional features of hypopituitarism, compounding the clinical picture attributable to AGHD ( 2 , 3 ). Available evidence shows benefit of GH replacement therapy (GHRT) on body composition, exercise

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-20-0098
Volume/Issue:
Volume 9: Issue 7
Open access
Nathalie Ly Department of Endocrinology and Reproductive Medicine, Reference Center for Rare Endocrine Diseases of Growth and Development, Reference Center for Gynecological Rare Diseases, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Paris, France
EndoERN, APHP Consortium Pitie Salpetriere Hospital, Necker Hospital, Paris, France

Search for other papers by Nathalie Ly in
Google Scholar
PubMed Close
,
Sophie Dubreuil Department of Endocrinology and Reproductive Medicine, Reference Center for Rare Endocrine Diseases of Growth and Development, Reference Center for Gynecological Rare Diseases, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Paris, France
EndoERN, APHP Consortium Pitie Salpetriere Hospital, Necker Hospital, Paris, France

Search for other papers by Sophie Dubreuil in
Google Scholar
PubMed Close
, and
Philippe Touraine Department of Endocrinology and Reproductive Medicine, Reference Center for Rare Endocrine Diseases of Growth and Development, Reference Center for Gynecological Rare Diseases, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Paris, France
EndoERN, APHP Consortium Pitie Salpetriere Hospital, Necker Hospital, Paris, France
Sorbonne University, Paris, France

Search for other papers by Philippe Touraine in
Google Scholar
PubMed Close

( 1 ). IGF-1 concentration is routinely used to assess both treatment’s efficacy and patient’s adherence when treated with GH replacement therapy (GHRT). The paramount importance of the GH–IGF axis on bone growth during childhood is well documented, as

Article Type:
Research Article
Collections:
Reproduction
DOI:
https://doi.org/10.1530/EC-22-0241
Volume/Issue:
Volume 11: Issue 12
Open access